tbuckley/cabot-search huggingface dataset:
Association of Medicaid Expansion With 1-Year Mortality Among Patients With End-Stage Renal Disease
Authors: Shailender Swaminathan, Benjamin D. Sommers, Rebecca Thorsness, Rajnish Mehrotra, Yoojin Lee, Amal N. Trivedi
Journal: JAMA (2018)

<h3>Importance</h3> The Affordable Care Act Medicaid expansion may be associated with reduced mortality, but evidence to date is limited. Patients with end-stage renal disease (ESRD) are a high-risk group that may be particularly affected by Medicaid expansion. <h3>Objective</h3> To examine the association of Medicaid expansion with 1-year mortality among nonelderly patients with ESRD initiating dialysis. <h3>Design, Setting, and Participants</h3> Difference-in-differences analysis of nonelderly patients initiating dialysis in Medicaid expansion and nonexpansion states from January 2011 to March 2017. <h3>Exposure</h3> Living in a Medicaid expansion state. <h3>Main Outcomes and Measures</h3> The primary outcome was 1-year mortality. Secondary outcomes were insurance, predialysis nephrology care, and type of vascular access for hemodialysis. <h3>Results</h3> A total of 142 724 patients in expansion states (mean age, 50.2 years; 40.2% women) and 93 522 patients in nonexpansion states (mean age, 49.7; 42.4% women) were included. In Medicaid expansion states, 1-year mortality following dialysis initiation declined from 6.9% in the preexpansion period to 6.1% after expansion (change, −0.8 percentage points; 95% CI, −1.1 to −0.5). In nonexpansion states, mortality rates were 7.0% before expansion and 6.8% after expansion (change, −0.2 percentage points; 95% CI, −0.5 to 0.2), yielding an adjusted absolute reduction in mortality in expansion states of −0.6 percentage points (95% CI, −1.0 to −0.2). Mortality reductions were largest for black patients (−1.4 percentage points; 95% CI, −2.2, −0.7;<i>P</i>=.04 for interaction) and patients aged 19 to 44 years (−1.1 percentage points; 95% CI, −2.1 to −0.3;<i>P</i>=.01 for interaction). Expansion was associated with a 10.5-percentage-point (95% CI, 7.7-13.2) increase in Medicaid coverage at dialysis initiation, a −4.2-percentage-point (95% CI, −6.0 to −2.3) decrease in being uninsured, and a 2.3-percentage-point (95% CI, 0.6-4.1) increase in the presence of an arteriovenous fistula or graft. Changes in predialysis nephrology care were not significant. <h3>Conclusions and Relevance</h3> Among patients with ESRD initiating dialysis, living in a state that expanded Medicaid under the Affordable Care Act was associated with lower 1-year mortality. If this association is causal, further research is needed to understand what factors may have contributed to this finding.
P3.12-07 MicroRNA Deregulation in a Typical Carcinoid Tumor: Potential Role of Immune Response and Invasion in Tumorigenesis
Authors: A. Seneda, R. Lopez Lapa, T. Felix, C. Oliveira, É. Hasimoto, D. Cataneo, A. Cataneo, J. De Faveri, S. Drigo, P. Dos Reis
Journal: Journal of Thoracic Oncology (2018)
A pilot study of gemcitabine, nab-paclitaxel, PEGPH20 (PAG) and rivaroxaban for advanced pancreatic adenocarcinoma: Interim safety and efficacy analysis
Authors: K. Yu, S. Mantha, C. Tjan, E. Kaufmann, R.B. Brenner, M. Lowery, G. Ku, N. Raj, M. Shcherba, Z. Goldberg, J. Li, A. Zervoudakis, A. Hamilton, E. Won, R.K.G. Do, E.M. O’Reilly
Journal: Annals of Oncology (2018)
A prospective evaluation of tolerability of niraparib dosing based on baseline body weight (BW) and platelet (plt) count: Blinded pooled interim safety data from the NORA study
Authors: X. Wu, J. Zhu, R. Yin, J. Yang, L. Wu, J. Liu, Z. Liu, J. Wang, Y. Gao, D. Wang, G. Lou, H. Yang, B. Kong, Y. Huang, Q. Zhou, H. Wen, J. Hou, C. Zhang, Y. Hei
Journal: Annals of Oncology (2019)
P2.09-06 Expression of PD-L1 on Routine Non-Small Cell Lung Carcinoma Sections: Comparative Assessment of SP263 (Ventana) and 22C3 (DAKO pharmDx)
Authors: A.M. Quinn, J. Gosney, P. Bishop, R. Bloor, C. Harreld, C. Mcnulty, R. Bowden, A. Moss, S. Forrest, A. Montero, A. Chaturvedi, L. Joseph, A. Paiva-Correia, H. Doran, P. Taniere, P. Crosbie, F. Blackhall, Y. Summers
Journal: Journal of Thoracic Oncology (2018)
Responses and durability of clinical benefit in triple negative breast cancer patients treated with pegilodecakin monotherapy or in combination with platinum plus taxane-based chemotherapy
Authors: A. Naing, K.A. Autio, G.S. Falchook, F. Meric-Bernstam, J.K. Litton, N.K. Ibrahim, A. Hung, M. Oft, J. Leveque, M.R. Patel
Journal: Annals of Oncology (2018)
Phase Ib KEYNOTE-200: A study of an intravenously delivered oncolytic virus, coxsackievirus A21 in combination with pembrolizumab in advanced NSCLC and bladder cancer patients
Authors: C.M. Rudin, H.S. Pandha, S. Gupta, M.R. Zibelman, W. Akerley, D. Day, A.G. Hill, R.E. Sanborn, S.J. O'Day, T.D. Clay, G.M. Wright, R. Jennens, D.E. Gerber, J.E. Rosenberg, C. Ralph, D.C. Campbell, B.D. Curti, E.V. Schmidt, M. Grose, D. Shafren
Journal: Annals of Oncology (2018)
Robustness of DLL3 (SP347) immunohistochemistry assay for detection of DLL3 protein in small cell lung cancer
Authors: C. Powell, E. Elgabry, B. Holmes, D. Tyree, R. Marati, B. Admire, T. Birdi, A.E. Hanlon Newell, B. Damadzadeh, D. Dalvi, R.S.P. Huang
Journal: Annals of Oncology (2018)
A phase III, randomized, open-label study to compare the efficacy of tislelizumab versus chemotherapy as second-line therapy for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC)
Authors: L. Shen, J.A. Ajani, S.-B. Kim, E. Van Cutsem, B. Guo, J. Song, V. Paton, K. Kato
Journal: Annals of Oncology (2018)
Pathological mucus and impaired mucus clearance in cystic fibrosis patients result from increased concentration, not altered pH
Authors: David B. Hill, Robert F. Long, William J. Kissner, Eyad Atieh, Ian C. Garbarine, Matthew R. Markovetz, Nicholas C. Fontana, Matthew Christy, Mehdi Habibpour, Robert Tarran, M. Gregory Forest, Richard C. Boucher, Brian Button
Journal: European Respiratory Journal (2018)

Cystic fibrosis (CF) is a recessive genetic disease that is characterised by airway mucus plugging and reduced mucus clearance. There are currently alternative hypotheses that attempt to describe the abnormally viscous and elastic mucus that is a hallmark of CF airways disease, including: 1) loss of CF transmembrane regulator (CFTR)-dependent airway surface volume (water) secretion, producing mucus hyperconcentration-dependent increased viscosity, and 2) impaired bicarbonate secretion by CFTR, producing acidification of airway surfaces and increased mucus viscosity. A series of experiments was conducted to determine the contributions of mucus concentration versus pH to the rheological properties of airway mucus across length scales from the nanoscopic to macroscopic. For length scales greater than the nanoscopic, i.e. those relevant to mucociliary clearance, the effect of mucus concentration dominated over the effect of airway acidification. Mucus hydration and chemical reduction of disulfide bonds that connect mucin monomers are more promising therapeutic approaches than alkalisation.
High-dose chemotherapy (HDCT) with hematopoietic stem cell transplantation (HSCT) in high-risk breast cancer (BC) patients with ≥4 involved axillary lymph nodes (ALN): 20-year follow-up of a randomized phase 3 study
Authors: T.G. Steenbruggen, L.C. Steggink, C.M. Seynaeve, J.J.M. van der Hoeven, M.J. Hooning, A. Jager, I.R. Konings, J.R. Kroep, W.M. Smit, V.C.G. Tjan-Heijnen, E. van der Wall, A.D. Bins, S.C. Linn, M. Schaapveld, F.E. van Leeuwen, C.P. Schroder, H. van Tinteren, E.G.E. de Vries, G.S. Sonke, J.A. Gietema
Journal: Annals of Oncology (2018)
Dynamic PEG–Peptide Hydrogels via Visible Light and FMN‐Induced Tyrosine Dimerization
Authors: Hung‐Yi Liu, Han D. Nguyen, Chien‐Chi Lin
Journal: Advanced Healthcare Materials (2018)

Abstract Photoresponsive hydrogels have become invaluable 3D culture matrices for mimicking aspects of the extracellular matrix. Recent efforts have focused on using ultraviolet (UV) light exposure and multifunctional macromers to induce secondary hydrogel crosslinking and dynamic matrix stiffening in the presence of cells. This contribution reports the design of a novel yet simple dynamic poly(ethylene glycol)–peptide hydrogel system through flavin mononucleotide (FMN) induced di‐tyrosine crosslinking. These di‐tyrosine linkages effectively increase hydrogel crosslinking density and elastic modulus. In addition, the degree of stiffening in hydrogels at a fixed PEG macromer content can be readily tuned by controlling FMN concentration or the number of tyrosine residues built‐in to the peptide linker. Furthermore, tyrosine‐bearing pendant biochemical motifs can be spatial‐temporally patterned in the hydrogel network via controlling light exposure through a photomask. The visible light and FMN‐induced tyrosine dimerization process produces a cytocompatible and physiologically relevant degree of stiffening, as shown by changes of cell morphology and gene expression in pancreatic cancer and stromal cells. This new dynamic hydrogel scheme should be highly desirable for researchers seeking a photoresponsive hydrogel system without complicated chemical synthesis and secondary UV light irradiation.
Modeling Disease with Human Inducible Pluripotent Stem Cells
Authors: Rodrigo Grandy, Rute A. Tomaz, Ludovic Vallier
Journal: Annual Review of Pathology Mechanisms of Disease (2018)

Understanding the physiopathology of disease remains an essential step in developing novel therapeutics. Although animal models have certainly contributed to advancing this enterprise, their limitation in modeling all the aspects of complex human disorders is one of the major challenges faced by the biomedical research field. Human induced pluripotent stem cells (hiPSCs) derived from patients represent a great opportunity to overcome this deficiency because these cells cover the genetic diversity needed to fully model human diseases. Here, we provide an overview of the history of hiPSC technology and discuss common challenges and approaches that we and others have faced when using hiPSCs to model disease. Our emphasis is on liver disease, and consequently, we review the progress made using this technology to produce functional liver cells in vitro and how these systems are being used to recapitulate a diversity of developmental, metabolic, genetic, and infectious liver disorders.
Final analysis of the Male-GBG54 study: A prospective, randomised multi-centre phase II study evaluating endocrine treatment with either tamoxifen +/- gonadotropin releasing hormone analogue (GnRHa) or an aromatase inhibitor + GnRHa in male breast cancer patients
Authors: M. Reinisch, S. Seiler, T. Hauzenberger, S. Schmatloch, H.-J. Strittmatter, D.-M. Zahm, C. Thode, C. Jackisch, D. Strik, V. Moebus, T. Reimer, B. Sinn, E. Stickeler, F. Marme, W. Janni, A. Kamischke, C. Rudlowski, V. Nekljudova, G. von Minckwitz, S. Loibl
Journal: Annals of Oncology (2018)
Phase III trial of chidamide, a subtype-selective histone deacetylase (HDAC) inhibitor, in combination with exemestane in patients with hormone receptor-positive advanced breast cancer
Authors: Z. Jiang, W. Li, X. Hu, Q. Zhang, T. Sun, S. Cui, S. Wang, Q. Ouyang, Y. Yin, C. Geng, Z. Tong, Y. Cheng, Y. Pan, Y. Sun, H. Wang, T. Ouyang, K. Gu, J. Feng, X. Wang
Journal: Annals of Oncology (2018)
Fluoropyrimidine (FP) + bevacizumab (BEV) + atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): Findings from Cohort 2 of MODUL – a multicentre, randomized trial of biomarker-driven maintenance treatment following first-line induction therapy
Authors: A. Grothey, J. Tabernero, D. Arnold, A. De Gramont, M.P. Ducreux, P.J. O'Dwyer, E. Van Cutsem, I. Bosanac, S. Srock, C. Mancao, F. Gilberg, J. Winter, H.-J. Schmoll
Journal: Annals of Oncology (2018)
Data-mining of 110 172 electronic patient records with the ConSoRe tool: An analysis of second primary cancer in a comprehensive cancer center
Authors: P. Heudel, T. Durand, B. Fervers, F. Gomez, M. Rivoire, T. Bachelot, L. Claude, C. Chassagne-Clement, F. Pilleul, T. Mognetti, Y. Devaux, J.-L. Soubirou, C. Lasset, D. Perol, G. Chvetzoff, C. Pezet, S. Beaupere, P. Zrounba, J.-Y. Blay
Journal: Annals of Oncology (2018)
JCSE01.09 Cluster Trial: Ph2 Biomarker-Integrated Study of Single Agent Alpelisib, Capmatinib, Ceritinib and Binimetinib in advNSCLC
Authors: Y. Wu, Q. Zhou, X. Zhang, H. Tu, B. Gan, B. Wang, C. Xu, H. Chen, M. Zheng, Z. Wang, X. Bai, Y. Sun, A. Myers, X. Lv, Y. Chakraborti, S. Zhao, J.-. Yang, J. Callister
Journal: Journal of Thoracic Oncology (2018)
P1.01-57 The Role of EGFR Mutation as a Prognostic Factor in Survival After Diagnosis of Brain Metastasis in NSCLC: A Systematic Review and Meta-Analysis
Authors: W. Li, T. Zhao, H. Xu, Z. Wang, Y. Xu, Y. Song, J. Wu, H. Xu, S. Yin, X. Liu, Z. Miao
Journal: Journal of Thoracic Oncology (2018)
A large multi-center, randomized, double-blind, crossover study in healthy volunteers to compare pharmacokinetics and pharmacodynamics of a proposed biosimilar pegfilgrastim with EU and US reference pegfilgrastim: Methodological approach
Authors: R. Nakov, S. Schussler, S. Schier-Mumzhiu, A. Skerjanec, A. Bellon, J. Wang, A. Krendyukov, G. Otto
Journal: Annals of Oncology (2018)
P1.01-68 Correlation of the Lung Immune Prognostic Index (LIPI) and PDL1 Status with Outcomes for Immune Checkpoint Inhibitors in Advanced NSCLC Patients
Authors: L. Mezquita, W. Park, K. Arbour, E. Auclin, L. Hendriks, D. Planchard, D. Saravia, S. Ponce Aix, E. Nadal, C. Audigier-Valette, S. Carnio, J. Adam, J.C. Ruffinelli, G. Zalcman, G. Numico, I. Sullivan, L. Paz-Ares, A. Dingemans, S. Novello, M. Hellmann, G. Lopes, B. Besse
Journal: Journal of Thoracic Oncology (2018)
MA16.01 Frequency and Genomic Context of Emerging Markers for Molecular Testing in Lung Adenocarcinoma in Cell-Free DNA NGS Analysis
Authors: L. Kiedrowski, V. Lam, Z. Piotrowska, A. Tsao, A. Wells, R. Lanman, V. Papadimitrakopoulou, R. Nagy
Journal: Journal of Thoracic Oncology (2018)
Accurate measurement of tumor mutation burden in liquid biopsy (bTMB) using a 500 gene panel
Authors: T. Jiang, S. Zhang, A. Jager, S. Katz, J. Lococo, P. Le, B. Andrian, C. Zhao, D. Baker, T. Pawlowski, S. Bilke
Journal: Annals of Oncology (2018)
P011 Concurrent ALK/EGFR Alterations in Chinese Lung Cancers: Frequency, Clinical Features, and Differential Response to Therapy
Authors: D. Wu, J. Liu, Z. Mu, L. Liu, K. Li, R. Jiang, P. Chen, Q. Zhou, M. Jin, Y. Ma, Y. Xie, J. Xiang, T. Zhang, B. Li, B. Yu
Journal: Journal of Thoracic Oncology (2018)
Prevalence and clinical profiles of disproportionate and proportionate microcephaly in China: a population-based cross-sectional study
Authors: Songying Shen, Wanqing Xiao, Lifang Zhang, Jinhua Lu, Anna Louise Funk, Si Tu, Jia Yu, Li Yang, Kar Keung Cheng, Huimin Xia, Xiu Qiu
Journal: The Lancet (2018)
Tumor mutation burden (TMB) estimation using small-sized targeted next-generation sequencing (NGS) to predict efficacy of immune checkpoint inhibitors (ICIs) for non-small cell lung cancer (NSCLC)
Authors: T. Ikeda, K. Ohashi, A. Sekine, Y. Ohe, T. Tsuda, Y. Kataoka, S. Hara, N. Okamoto, M. Kodani, S. Matsumoto, K. Goto
Journal: Annals of Oncology (2018)
Phase III study of gefitinib (G) versus gefitinib+carboplatin+pemetrexed (GCP) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009)
Authors: M. Seike, A. Inoue, S. Sugawara, S. Morita, Y. Hosomi, S. Ikeda, K. Watanabe, K. Takahashi, Y. Fujita, T. Harada, K. Minato, K. Takamura, K. Kobayashi, T. Nukiwa
Journal: Annals of Oncology (2018)
Breast cancer (BC) treatment (tx) with everolimus (EVE) and exemestane (EXE) in hormone receptor positive (HR+)/ HER2-negative (HER2−) postmenopausal women: Final analysis of the French observational TANGO study
Authors: C. Villanueva, G. Yazbek, P. Beuzeboc, E. Viel, N. Dohollou, E. Luporsi, J.-C. Eymard, E. Levy, M.-A. Mouret-Reynier, L.-M. Dourthe, E. Malaurie, M. Madelenat, A. Denden, E.-C. Antoine
Journal: Annals of Oncology (2018)
Neoadjuvant ipilimumab plus nivolumab in early stage colon cancer
Authors: M. Chalabi, L.F. Fanchi, J.G. Van den Berg, G.L. Beets, M. Lopez-Yurda, A.G. Aalbers, C. Grootscholten, P. Snaebjornsson, M. Maas, M. Mertz, E. Nuijten, M. Kuiper, M. Kok, M.E. Van Leerdam, T.N. Schumacher, E.E. Voest, J.B. Haanen
Journal: Annals of Oncology (2018)
Estimates of the Global Burden of Ambient PM2.5, Ozone, and NO2 on Asthma Incidence and Emergency Room Visits
Authors: Susan C. Anenberg, Daven K. Henze, Veronica Tinney, Patrick L. Kinney, William Raich, Neal Fann, Chris S. Malley, Henry Roman, Lok Lamsal, Bryan Duncan, Randall V. Martin, Aaron van Donkelaar, Michael Brauer, Ruth Doherty, Jan Eiof Jonson, Yanko Davila, Kengo Sudo, Johan C.I. Kuylenstierna
Journal: Environmental Health Perspectives (2018)

Asthma is the most prevalent chronic respiratory disease worldwide, affecting 358 million people in 2015. Ambient air pollution exacerbates asthma among populations around the world and may also contribute to new-onset asthma.We aimed to estimate the number of asthma emergency room visits and new onset asthma cases globally attributable to fine particulate matter ([Formula: see text]), ozone, and nitrogen dioxide ([Formula: see text]) concentrations.We used epidemiological health impact functions combined with data describing population, baseline asthma incidence and prevalence, and pollutant concentrations. We constructed a new dataset of national and regional emergency room visit rates among people with asthma using published survey data.We estimated that 9–23 million and 5–10 million annual asthma emergency room visits globally in 2015 could be attributable to ozone and [Formula: see text], respectively, representing 8–20% and 4–9% of the annual number of global visits, respectively. The range reflects the application of central risk estimates from different epidemiological meta-analyses. Anthropogenic emissions were responsible for [Formula: see text] and 73% of ozone and [Formula: see text] impacts, respectively. Remaining impacts were attributable to naturally occurring ozone precursor emissions (e.g., from vegetation, lightning) and [Formula: see text] (e.g., dust, sea salt), though several of these sources are also influenced by humans. The largest impacts were estimated in China and India.These findings estimate the magnitude of the global asthma burden that could be avoided by reducing ambient air pollution. We also identified key uncertainties and data limitations to be addressed to enable refined estimation. https://doi.org/10.1289/EHP3766.
Influence of sex on chemotherapy efficacy and toxicity in oesophagogastric (OG) cancer: A pooled analysis of four randomised trials
Authors: M. Davidson, A.D. Wagner, K. Kouvelakis, N. Starling, I. Chau, D. Watkins, S. Rao, C. Peckitt, D. Cunningham
Journal: Annals of Oncology (2018)
Abstract P048: Effects of Aerobic Exercise on Oxidative Stress in the Kidneys of Type2 Diabetic Rats
Authors: Daisuke Ito, Pengyu Cao, Takaaki Kakihana, Emiko Sato, Yoshikazu Muroya, Yoshiko Ogawa, Gaizun Hu, Tadashi Ishii, Osamu Ito, Masahiro Kohzuki, Hideyasu Kiyomoto
Journal: Circulation (2016)

Objective: Aerobic exercise is known to have multiple beneficial effects including renal protection in type 2 diabetes mellitus and obesity. However, the mechanisms regulating these actions of aerobic exercise remain unclear. The present study evaluated the effects of chronic aerobic exercise on early stage of diabetic nephropathy focusing on renal oxidative stress and nitric oxide (NO), using Zucker diabetic fatty (ZDF) rats as an animal model of obese type 2 diabetes. Methods: Male ZDF rats (6 weeks old) underwent forced treadmill exercise for 8 weeks (Ex-ZDF). Sedentary ZDF (Sed-ZDF) and Zucker lean (Sed-ZL) rats served as controls. After the last exercise session, all rats were subjected to an intra-peritoneal glucose tolerance test. Result: Exercise ameliorated hyperglycemia with increased insulin secretion, and raised the values of homeostasis model assessment for β-cell function (HOMA-β) in ZDF rats. Exercise also reduced albumin excretion and normalized creatinine clearance in ZDF rats. Endothelial (e) and neuronal (n) NO synthase (NOS) protein expression, and NOS activity in the kidneys of Sed-ZDF rats were lower compared with Sed-ZL rats, while both NOS expression and NOS activity were upregulated by exercise in ZDF rats. Although there was no significant difference in plasma levels of adiponectin between the groups, plasma levels of leptin were significantly higher in the Ex-ZDF group compared with the Sed-ZL and Sed-ZDF groups. Exercise decreased plasma and urinary thiobarbituric acid-reactive substances (TBARS) as an index of lipid peroxidation in ZDF rats. Additionally, renal nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity and expression of p47phox protein were significantly higher in the kidneys of the Sed-ZDF group compared with the Sed-ZL group, and there was no significant difference between the Ex-ZDF and Sed-ZL groups. Immunoblots for Nox4, Nox2, namely gp91phox and p22phox protein were undetected in the kidneys of the Sed-ZDF and Ex-ZDF group as well as the Sed-ZL group. In addition, expression of nitrotyrosine as an index of peroxynitrite (ONOO–) formation was significantly lower in the kidneys of the Sed-ZDF group compared with the Sed-ZL group, and was significantly higher in the Ex-ZDF group compared with the Sed-ZDF group. Further, morphometric evidence of renal damage was alleviated in response to exercise. Conclusion: Upregulated NOS activity and NOS protein, and ameliorated NADPH oxidase activity and p47phox protein in the kidneys may be potential mechanisms by which chronic aerobic exercise can reduced early diabetic nephropathy in ZDF rats. Chronic aerobic exercise does have beneficial effects and may be a novel therapeutic approach for preventing the development of renal dysfunction in patients with type 2 diabetes mellitus and obesity.
MA05.05 Photon-Based Cardiac Sparing Via Volumetric Modulated Arc Therapy in Thoracic Radiation Therapy for Locally Advanced Non-Small Cell Lung Cancer
Authors: M. Ferris, K. Sykes, O. Kayode, J. Wolf, R. Press, J. Switchenko, W. Curran, K. Higgins
Journal: Journal of Thoracic Oncology (2018)
P3.01-111 Efficacy and Safety of Cytotoxic Drug Chemotherapy After First-Line EGFR-TKI in Elderly Patients with NSCLC Harboring Sensitive EGFR Mutations
Authors: Y. Yamada, H. Imai, T. Sugiyama, H. Minemura, K. Kaira, K. Kanazawa, T. Kasai, T. Kaburagi, K. Minato
Journal: Journal of Thoracic Oncology (2018)
Sarcopenia and inflammation predicts survival in advanced stage cancer patients (pts) treated with immunotherapy (IO)
Authors: M.A. Bilen, D.J. Martini, J.M. Shabto, Y. Liu, A.I. Khan, M.A. Williams, C. Lewis, H.H. Collins, H. Kissick, B.C. Carthon, M. Akce, W.L. Shaib, O.B. Alese, D.H. Lawson, R. Kudchadkar, B. El-Rayes, S.S. Ramalingam, T.K. Owonikoko, R.D. Harvey, V.A. Master
Journal: Annals of Oncology (2018)
QUADRA: A phase II, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) in 4th or later line of therapy: Results from the tBRCAmut subset
Authors: K.N. Moore, A.A. Secord, M. Geller, D.S. Miller, N.G. Cloven, G.F. Fleming, A.E. Wahner Hendrickson, M. Azodi, P. DiSilvestro, A. Oza, M. Cristea, J.S. Berek, J.K. Chan, B.J. Rimel, Y. Li, K. Luptakova, R. Clark, U.A. Matulonis, B.J. Monk
Journal: Annals of Oncology (2018)